Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 20, 2021

View Archived Issues

Targeting integrated epigenetic/metabolic pathways lowers EZHIP in a subset of PFA ependymomas

Calpain inhibitor BLD-2736 is protective against spinocerebellar ataxia type 3

Drosophila model reveals damaging effect of tumors on blood-brain barrier permeability

HPK1 inhibitor RGT-197 potentiates antitumor immunity

ONTC-534 shows promising activity in prostate cancer models

MRTX-1719 demonstrates antitumor activity in MTAP del xenograft models

SNIP1 gene variant linked to neurodevelopmental disorder in Amish families

Janssen Pharmaceutica discloses MGLL inhibitors

SRI International patents new lipoxygenase inhibitors

Dana-Farber Cancer Institute presents IRAK-1 inhibitors

Medshine Discovery synthesizes new DNA-PK inhibitors

Chengdu Novo Sinta Biotechnology describes kappa-opioid receptor agonists

Design, synthesis and optimization of potent STAT3 degraders for the treatment of cancer

CRyPTIC project identifies mutations conferring resistance to tuberculosis treatments

NDEL1 gene may play a role in lissencephaly

Debiopharm awarded further funding to target N. gonorrhoeae

Missense mutation in the MMP14 gene causes autosomal dominant hypotrichosis

Sanaria and Seattle Children's Research Institute partner on genetically attenuated malaria vaccines

EDP-235 demonstrates potent antiviral activity against SARS-CoV-2 in cellular models

Retrotope reports data on RT-011 in animal models of retinal degeneration

TCR2 Therapeutics enhances TRuC-T cells with IL-15 expression

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 27, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Sichuan Kelun Pharmaceutical Research Institute discovers GPR6 inverse agonists
BioWorld Science
Sichuan Kelun Pharmaceutical Research Institute Co. Ltd. has identified G protein-coupled receptor 6 (GPR6) inverse agonists reported to be useful for the...